-
Pope condemns 'indifference' towards migrants on Canaries trip
-
UK defence minister John Healey announces shock resignation in funding row
-
Stocks diverge, oil falls as traders weigh Iran, rates outlook
-
New Zealand's Conway jets home between Tests to attend birth of child
-
McKeown eyeing world record after sizzling at Australian trials
-
Carbon dioxide removal slow to take off, alarming scientists
-
O'Neill confirmed as Celtic's permanent boss after double triumph
-
Bangladesh chase 192 in 41 overs after Australia collapse in rain-hit ODI
-
Relegated Wolves sack Edwards after seven months in charge
-
Wimbledon prize money pot increased to £64.2 million
-
Iran's World Cup team finds supporters in Mexico
-
Sweden withdraws controversial proposal to jail 13-year-olds
-
'Racist thuggery' condemned after second night of disorder in N.Ireland
-
Economic pressures 'manageable': Indonesian deputy finance minister
-
G7 allies seek to bridge divide with Trump at France summit
-
Serena's comeback at Queen's over after Mboko injury withdrawal
-
Pope arrives in Spain's Canary Islands to meet migrants
-
Scientists warn of record heat, threats to climate monitoring
-
Iran warns Mideast truce 'practically meaningless' after US strikes
-
Russia unblocks Roblox after widespread child anger
-
Sweden withdraws disputed proposal to jail 13-year-olds
-
UK probes Ryanair over fees for parents to sit with children
-
Small, efficient and revolutionary: The IPOP electric car from Alsace
-
Solomon Islands says China security pact to remain secret
-
Tharp, 20, breaks 110m hurdles world record at NCAA championships
-
Thailand sentences Chinese Uyghurs to death in 2015 shrine bombing case
-
'Victory' or 'peace': Russian Orthodox believers question Church's war stance
-
Ukrainian mother's agony highlights abuse and weaponisation of draft
-
Swiss to vote on stricter rules for conscientious objection
-
'Resilient' Knicks on brink of NBA title after record rally
-
Suspense surrounds Swiss anti-immigration vote
-
Rising costs and competition threaten GoPro
-
A taste of home: Zimbabwe restaurants revive traditional food
-
AI gold rush upends San Francisco housing market
-
'It just hurts': Spurs search for answers after epic collapse against Knicks
-
World Cup set for kickoff after high ticket prices, visa issues dog buildup
-
Several arrested outside NBA Finals in New York
-
Knicks stage historic comeback to beat Spurs, one win from NBA title
-
The Indian workers training AI robots to take their jobs
-
AI robot cleaners leave the lab for China's living rooms
-
In ageing South Korea, AI dolls care for the elderly
-
S.Korea hits Coupang with record fine over e-commerce data leak
-
Stocks drop, oil rises as Iran and rate worries dog traders
-
Giants under pressure in open Women's T20 World Cup
-
Antonelli seeks sixth straight win at Barcelona Grand Prix
-
Russia's conscripts recount pressure to fight in Ukraine
-
Twenty-two countries tell Iran to stop attacks 'on our soil'
-
ECB set to hike interest rates to tame Iran war inflation surge
-
Pilots demand answers ahead of Air India crash anniversary
-
Iran's World Cup super fans excited for football despite the war
Trump signs order to fast-track research on psychedelic drugs
US President Donald Trump on Saturday announced an easing of restrictions on research into psychedelic drugs -- such as so-called "magic mushrooms" -- that have shown promise in treating people with mental health conditions.
Flanked by US Health Secretary Robert F. Kennedy Jr, top medical officials and podcaster Joe Rogan, who has pushed for access to the drugs, Trump signed an executive order that would help federal researchers cut through the red tape to allow for quicker studies.
The president said the order would "clear away unnecessary bureaucratic hurdles, improve data sharing among the FDA (Food and Drug Administration) and the Department of Veterans Affairs and facilitate fast rescheduling of any psychedelic drugs that become FDA approved."
Currently, many psychedelics including LSD and psilocybin ("magic mushrooms") are classified -- or "scheduled" -- as having high abuse and addiction potential, and are not approved for medical use, limiting the ability for scientists to study them.
If the FDA, which is charged with regulating pharmaceuticals in the United States, officially finds a medical benefit for some of the psychedelics, they could be rescheduled, allowing for greater clinical use.
The order only provides for accelerated research and does not immediately require law enforcement authorities to reclassify the drugs, meaning therapeutic use will not expand immediately.
In recent years, there has been a growing push to research the effects of the drugs in treating people -- especially war veterans -- with difficult anxiety and depression cases, especially those who had experienced traumatic stress.
Many veterans and other patients have complained that traditional antidepressant cocktails not only fail to work but change their personalities in ways that alienate them from their friends and family.
In 2023, 6,398 veterans took their own lives, the Department of Veterans Affairs said.
During the signing ceremony at the White House, Trump pointed to one drug called ibogaine, claiming patients who had taken it "experienced an 80 to 90 percent reduction in symptoms of depression and anxiety within one month."
"Can I have some, please?" he joked.
The full extent of the benefits and potential side effects of psychedelic medications is not yet known, since research has been restricted.
While many are thought to show promising mental health benefits, there are risks. Ibogaine, for instance, is thought to potentially damage the heart.
If you are a US veteran in need of help, or concerned about one, you can dial 988 and press 1, or visit www.veteranscrisisline.net.
L.AbuAli--SF-PST